German pharmaceutical company Bayer AG announced on Tuesday that its sales for the third quarter of fiscal 2022 came in at €11.3 billion, jumping 15.3% on an annual basis.
In addition, net income from continuing and discontinued operations in the third trimester surged from €85 million, recorded in the same period of 2021, to €546 million. Diluted earnings per share skyrocketed 522% year over year to €0.56.
"We made encouraging progress with our innovative products in the third quarter. There have been no material changes in our assessment of risks from the impact of the Russia-Ukraine war compared with the previous quarter," the report noted. Chairman of the Board of Management Werner Baumann commented that "despite rising inflation and global supply chain problems, we were again able to boost sales and earnings."
